繁体中文
设为首页
加入收藏
当前位置:药品说明书与价格首页 >> 用药警示 >> 潜在致吐的抗肿瘤药

潜在致吐的抗肿瘤药

2009-10-27 17:08:08  作者:  来源:互联网  浏览次数:80  文字大小:【】【】【
简介: EMETOGENIC POTENTIAL OF ANTINEOPLASTIC AGENTS High Risk (>90% frequency without antiemetics) • AC combination: Doxorubicin (Adriamycin) or Epirubicin (Ellen ...

 EMETOGENIC POTENTIAL OF ANTINEOPLASTIC AGENTS

 
High Risk (>90% frequency without antiemetics)

• AC combination: Doxorubicin (Adriamycin) or Epirubicin
(Ellence) + Cyclophosphamide (Cytoxan, Neosar)

• Altretamine (HMM, Hexalen)

• Carmustine (BCNU, BiCNU) >250 mg/m2

• Cisplatin (CDDP, Platinol, Platinol-AQ) ≥50 mg/m2

• Cyclophosphamide (CTX, Cytoxan, Neosar) >1,500 mg/m2

• Dacarbazine (DTIC, DTIC-Dome)

• Mechlorethamine (Mustargen)

• Procarbazine (Matulane) oral

• Streptozocin (Zanosar)

Moderate Risk (30–90% frequency without antiemetics)

• Aldesleukin (IL-2, Proleukin) >12–15 million units/m2

• Amifostine (Ethyol) >300 mg/m2

• Arsenic trioxide (As2O3, Trisenox)

• Azacitidine (Vidaza)

• Busulfan (Busulfex) high dose >4 mg/d

• Carboplatin (Paraplatin)

• Carmustine (BCNU, BiCNU) ≤250 mg/m2

• Cisplatin (CDDP, Platinol, Platinol-AQ) <50 mg/m2

• Cyclophosphamide (CTX, Cytoxan, Neosar) ≤1,500 mg/m2

• Cyclophosphamide (CTX) oral

• Cytarabine (ARA-C, Cytosar-U) >1 g/m2

• Dactinomycin (actinomycin D, Cosmegen)

• Daunorubicin (Cerubidine, Daunomycin)

• Doxorubicin (Adriamycin)

• Epirubicin (Ellence)

• Etoposide (VP-16, VePesid) oral

• Idarubicin (Idamycin)

• Ifosfamide (Ifex)

• Imatinib (Gleevec) oral*

• Irinotecan (CPT-11, Camptosar)

• Lomustine (CCNU, CeeNU)

• Melphalan (L-PAM, Alkeran) >50 mg/m2 IV

• Methotrexate (MTX) 250 to >1,000 mg/m2

• Oxaliplatin (Eloxatin) >75 mg/m2

• Temozolomide (Temodar) oral

• Vinorelbine (Navelbine) oral

Low Risk (10–30% frequency without antiemetics)

• Amifostine (Ethoyl) ≤300 mg

• Bexarotene (Targretin)

• Capecitabine (Xeloda) oral

• Cetuximab (C225, Erbitux)

• Cytarabine (ARA-C, Cytosar-U) ≤1 g/m2

• Docetaxel (Taxotere)

• Doxorubicin liposomal (Doxil)

• Etoposide (VP-16, Etopophos, VePesid) IV

• Fludarabine (Fludara) oral

• Fluorouracil (5-FU)

• Gemcitabine (Gemzar)

• Methotrexate (MTX) >50 mg/m2 to <250 mg/m2

• Mitomycin (MTC, Mitozytrex, Mutamycin)

• Mitoxantrone (DHAD, Novantrone)

• Paclitaxel (Taxol)

• Paclitaxel albumin (Abraxane)

• Pemetrexed (Alimta)

• Topotecan (Hycamtin)

Minimal Risk (<10% frequency without antiemetics)

• Alemtuzumab (Campath)

• Asparaginase (Elspar)

• Bevacizumab (Avastin)

• Bleomycin (Blenoxane)

• Bortezomib (Velcade)

• Busulfan (Busulfex)

• Chlorambucil (Leukeran) oral

• Cladribine (2-CdA, Leustatin)

• Dasatinib (Sprycel)

• Decitabine (Dacogen)

• Denileukin diftitox (Ontak)

• Dexrazoxane (Totect, Zinecard)

• Erlotinib (Tarceva)

• Fludarabine (Fludara) IV

• Gefitinib (Iressa)

• Gemtuzumab ozogamicin (Mylotarg)

• Hydroxyurea (Hydrea) oral

• Interferon alpha (IFN-alpha, Intron A)

• Lenalidomide (Revlimid)

• Melphalan (L-PAM, Alkeran) low dose oral

• Methotrexate (MTX) ≤50 mg/m2

• Nelarabine (Arranon)

• Pentostatin (Nipent)

• Rituximab (Rituxan)

• Sorafenib (Nexavar)

• Sunitinib (Sutent)

• Thalidomide (Thalomid)

• Thioguanine (6-TG,Tabloid) oral

• Trastuzumab (Herceptin)

• Vinblastine (VLB)

• Vincristine (VCR)

• Vinorelbine (Navelbine) IV

责任编辑:admin


相关文章
潜在致吐的抗肿瘤药
 

最新文章

更多

· MRI检出:阿利吉仑增加斑...
· 美修改吗替麦考酚酯说明...
· FDA更新来那度胺发生新恶...
· FDA警告:西地那非禁用于...
· 美国FDA再次警告艾塞那肽...
· FDA发布达伐吡啶致 癫痫...
· 日本增加干扰素使用禁忌
· FDA:来那度胺增加新发恶...
· FDA建议谨慎合用甲氨蝶呤...
· FDA发布芬戈莫德安全通告

推荐文章

更多

· MRI检出:阿利吉仑增加斑...
· 美修改吗替麦考酚酯说明...
· FDA更新来那度胺发生新恶...
· FDA警告:西地那非禁用于...
· 美国FDA再次警告艾塞那肽...
· FDA发布达伐吡啶致 癫痫...
· 日本增加干扰素使用禁忌
· FDA:来那度胺增加新发恶...
· FDA建议谨慎合用甲氨蝶呤...
· FDA发布芬戈莫德安全通告

热点文章

更多